With the publication of Supplement 9.3 of the European Pharmacopoeia, the USB version will be replaced by a downloadable version.
The EDQM will hold an international symposium on 10-11 October 2017 in Strasbourg (France) to present and discuss recent achievements, as well as future perspectives, of the Ph. Eur. in the microbiology field.
During a seminar coorganised with the European Medicines Agency (EMA), the EDQM clarified further the role that Ph. Eur. monographs play in the assessment of biosimilars.
With the implementation of the ICH Q3D guideline on elemental impurities, the control of elemental impurities is undergoing a shift in paradigm, moving away from pure substance-based testing towards a holistic control strategy in the finished product.
The EDQM is pleased to announce that the 2016 issue of Pharmeuropa Bio & Scientific Notes is available online
The Ph. Eur. Commission unanimously decided to grant Japan observer status. This brings to 30 the number of observers, from 6 continents.
The chapter on Chemical Imaging (5.24) was adopted by the European Pharmacopoeia Commission at the end of November 2016.
Pharmeuropa contains draft pharmacopoeial texts for which the European Pharmacopoeia Commission is seeking comment.
The EDQM is proud to announce that its Quality Management System has been recognised compliant to the 2015 version of the ISO 9001 standard.
The P4Bio pilot phase came to a successful conclusion at the 156th Session of the European Pharmacopoeia Commission, with the adoption of the monograph for Etanercept (2895).
During its 156th Session, the Ph.Eur. Commission unanimously decided to grant India observer status. This brings to 29 the number of observers, from 6 continents.
At its 156th Session the European Pharmacopoeia Commission adopted the monograph on Sodium pertechnetate (99mTc) (accelerator-produced) injection (2891).
The recent adoption at its 156th session on 22-24 November of new texts demonstrates the Commission’s commitment to the replacement, reduction and refinement of animal tests in the quality control of medicines.
At its 156th session (22-23 November 2016), the European Pharmacopoeia Commission approved the priorities for the three coming years, which are aimed at maintaining the scientific excellence, leading role and influence of the Ph. Eur. worldwide.
The meeting of the Pharmacopoeial Discussion Group (PDG) [European Pharmacopoeia (Ph. Eur.), Japanese Pharmacopoeia (JP), and the United States Pharmacopeia (USP)] was hosted by JP in Tokyo, Japan, 24-26 October 2016.